Literature DB >> 3130070

Hypoxic cells as specific drug targets for chemotherapy.

K A Kennedy1.   

Abstract

Hypoxic cells exist in solid tumors in regions of poor vascularity and are likely to be exposed to insufficient concentrations of chemotherapeutic agents. Furthermore, because these cells may be cycling very slowly or may be quiescent, they may not be sensitive to agents which are most active in proliferating cells. Under conditions of reoxygenation, hypoxic cells which have survived therapy may re-enter the cell cycle and repopulate a tumor which had shown responsiveness. Three classes of agents have recently been shown to be selectively toxic to hypoxic cells in vitro. For some of these agents, combinations of hypoxic cell-selective drugs and agents with selectivity for well oxygenated cells have demonstrated improved tumor cell kill in solid transplantable rodent tumor systems. The selectivity of these classes of drugs apparently stems from enhanced activation of the drug under hypoxic conditions. Although all of these drugs exhibit selectivity, the wide divergence in the therapeutic ratios for the individual agents suggests that it may be possible to develop newer agents that are highly toxic to hypoxic cells with little toxicity for normal tissues.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3130070

Source DB:  PubMed          Journal:  Anticancer Drug Des        ISSN: 0266-9536


  18 in total

Review 1.  The challenge of drug resistance in cancer treatment: a current overview.

Authors:  Michail Nikolaou; Athanasia Pavlopoulou; Alexandros G Georgakilas; Efthymios Kyrodimos
Journal:  Clin Exp Metastasis       Date:  2018-05-24       Impact factor: 5.150

Review 2.  Cellular pharmacology of quinone bioreductive alkylating agents.

Authors:  S Rockwell; A C Sartorelli; M Tomasz; K A Kennedy
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

3.  THNLA-1 as radio/chemosensitiser of EMT-6 tumours in mice.

Authors:  M V Papadopoulou; M Ji; W D Bloomer
Journal:  Br J Cancer Suppl       Date:  1996-07

4.  Preferential DNA cleavage under anaerobic conditions by a DNA-binding ruthenium dimer.

Authors:  Thamara K Janaratne; Abhishek Yadav; Fiona Ongeri; Frederick M MacDonnell
Journal:  Inorg Chem       Date:  2007-03-28       Impact factor: 5.165

Review 5.  Bioreductive activation of quinones: a mixed blessing.

Authors:  A S Koster
Journal:  Pharm Weekbl Sci       Date:  1991-06-21

6.  The effects of O6-benzylguanine and hypoxia on the cytotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea in nitrosourea-resistant SF-763 cells.

Authors:  A Sarkar; M E Dolan; G G Gonzalez; L J Marton; A E Pegg; D F Deen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069).

Authors:  M Binger; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

8.  Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy.

Authors:  Sarah Crawford
Journal:  Front Pharmacol       Date:  2013-06-25       Impact factor: 5.810

9.  Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.

Authors:  A V Patterson; M P Saunders; E C Chinje; D C Talbot; A L Harris; I J Strafford
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Immunohistochemical detection of a hypoxia marker in spontaneous canine tumours.

Authors:  J M Cline; D E Thrall; R L Page; A J Franko; J A Raleigh
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.